“It has been an exciting 15 years for renal cell carcinoma,” noted Eric Jonasch, MD, Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, and Director of the Von Hippel–Lindau Clinical Center at The University of Texas MD Anderson Cancer Center. “When I started my career,” he added, “we had 1 approved agent; now we have 8.” Dr. Jonasch is Vice-Chair of the NCCN Guidelines Panels for Kidney and Testicular Cancers.
During his presentation at the NCCN 20th Annual Conference, Dr. Jonasch focused on the host of systemic therapies now available for metastatic renal cell carcinoma (RCC) that have category 1 evidence in the most recent version of the NCCN Guidelines. He stated that clinical study data do not support the use of adjuvant therapy for RCC in 2015. With the advent of various antiangiogenic agents and mTOR inhibitors, investigators have moved past the cytokine therapy era, he noted. In the upcoming years, Dr. Jonasch predicted, the next wave of clinical trials will test the combination of novel immunotherapies with antiangiogenic agents in the hope of further improving patient outcomes.
MotzerRJHutsonTETomczakP. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol2009;27:3584–3590.
SteinbergCNDavisIDMardiakJ. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol2010;28:1061–1068.
RiniBIHalabiSRosenbergJ. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206 [abstract]. J Clin Oncol2009;27(Suppl):Abstract LBA5019.
KayAMotzerRFiglinR. Updated data from a phase III randomized trial of everolimus (RAD001) versus placebo in metastatic renal cell carcinoma [abstract]. Presented at the 2009 ASCO Genitourinary Cancers Symposium; February26–282009; Orlando, FL. Abstract 278.
RiniBIEscudierBTomczakP. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial. Lancet2011;378:1931–1939.
ChoueiriTKVaishampayanURosenbergJE. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol2013;31:181–186.
PostowMACallahanMKWolchokJD. Immune checkpoint blockade in cancer therapy[published online ahead of print January 20 2015]. J Clin Oncolpii: JCO.2014.59.4358.
MotzerRJRiniBIMcDermottDF. Nivolumab for metastatic renal cell carcinoma results of a randomized phase II trial. J Clin Oncol2015;33:1430–1437.